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Abstract
Diabetic patients are at a three-fold increased risk of developing active
tuberculosis (TB) disease. Bi-directional screening for both diseases is there-
fore recommended byWHO.However, there is no consensus which screen-
ingmodality is best suited under service conditions. The Concurrent Tuber-
culosis and Diabetes Mellitus (TANDEM) consortium has suggested a two-
step diagnostic algorithm where all patients with random plasma gluc-
ose values above 6.1 mmol/L receive point-of-care glycated haemoglobin
(HbA1C) testing. Here, we aimed to evaluate random plasma glucose test-
ing as first-step screening tool among disadvantaged TB patients in urban
slums in East, West, and South New Delhi not receiving treatment through
the national TB programme. A pilot project on diabetes screening was suc-
cessfully implemented. A total of 1773 TB patients underwent screening
and yielded 336 participants with glucose values above the threshold of 6.1
mmol/L. We concluded that random glucose sampling is feasible in our
setting and needs to be supplemented with point-of-care Hb1AC testing to
reliably diagnose diabetes, which was not available locally.
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Sir,
Mycobacterium tuberculosis causes more deaths globally than any other
single infectious agent1. India has the highest tuberculosis (TB) burden
worldwide with 1,9 million cases in 2016 and an incidence rate of 211 cases
per 100,000 population2. In the absence of efficacious vaccines and reliable
biomarkers, applying antimicrobials for a course of six or more months
under directly observed treatment has been the mainstay of TB treatment
in India. TB can co-occur along with other conditions such as HIV infec-
tion or nosocomial acquisition of gram-negative pathogens during lengthy
therapy3,4. Non-communicable diseases like diabetes have increasingly
been recognised as important risk factors for TB and poor treatment out-
comes5. While the link between TB and diabetes has been described many
decades ago6, several recent epidemiological studies and systematic re-
views have confirmed the association between diabetes and the ensuing
three-fold increased risk to develop TB7. In recognition of this, WHO re-
commends bi-directional screening of all TB patients for diabetes8. How-
ever, at which point in treatment best to screen and which diagnostic tools
to use is unknown. The Concurrent Tuberculosis and Diabetes Mellitus
(TANDEM) consortium recently suggested a two-step diagnostic algorithm
where all patients with random plasma glucose values above 6.1 mmol/L
receive point-of-care glycated haemoglobin (HbA1C) testing9. With labor-
atory based HbA1C as gold-standard, this two-step combination resulted
in a sensitivity and specificity of over 90% to detect diabetes.
The private sector in India plays a major role in the management of
TB; indeed, two-thirds of TB patients receive their treatment by private
sector entities necessitating high out-of-pocket expenditures10. Operation
ASHA (OpASHA), a not-for-profit organisation founded in 2006, is dedic-
ated to bring free TB treatment to disadvantaged patients in urban slums
and rural-poor communities. OpASHA treatment centres whomight other-
wise not seek treatment offered by the Revised National Tuberculosis Con-
trol Programme (RNTCP) or private practices. OpASHA currently serves
15 million people in 10 Indian states and 8 Cambodian provinces with a
team of 250 field workers, 150 community partners, and about 4000 vil-
lage health care workers. A biometric attendance terminal wrapped in
an Android application featuring automated cell-phone messaging to pa-
tients and digitised records is employed. Thus, OpASHA hasmarkedly im-
proved treatment adherence with few missed doses among its patients, ul-
timately achieving similar treatment outcomes as the national TB program11.
Here, we aimed to investigate the feasibility of randomglucose sampling,
as first of a two-step diagnostic approach proposed by the TANDEM con-
sortium, among this slum-residing TB patients. OpASHA initiated a pilot
intervention in its treatment centres in East, West, and South Delhi, con-
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Figure 8.1: Waffle plot showing the total yield (n = 1773) of a glucose screen-
ing among tuberculosis patients in New Delhi slums stratified by blood
glucose values. The figure shows the proportion of patients with normal
glucose values, elevated glucose values that require further testing as well
as diabetic patients defined by glucose values above 11.1 mmol/L. 95%
confidence intervals shown in brackets in %. Data analysed and visualised
with the R package waffle
Patient characteristics
Random plasma glucose
Total≤ 6.1 mmol/L >6.1 ≤ 11.1 mmol/L >11.1 mmol/L











Female 0.43ns 0.41ns 0.44ns 0.43
Male 0.56ns 0.59ns 0.56ns 0.57
Table 8.1: Descriptive statistics of screened population stratified by glucose
values. n = number; Wilcoxon Signed-Rank non-parametric test was used
for the variables Age and Gender. * = p <0.05, ** = p <0.01, *** = p <0.001,
ns = not significant; in 9 instances the glucose results were excluded due to
probably erroneous entries (>27.8 mmol/L); for 5 entries gender informa-
tion was unavailable
sisting of staff training, glucometer and test kit supply and minor infra-
structure investments to allow blood glucose testing and counselling. The
aim of the training module was to to train field workers on how to meas-
ure blood glucose and provide appropriate counselling. Glucometers were
procured fromAccu-Check (Glucometers, Active Test strips and retractable
Uno Lancets; all Roche Diagnostics, Basel, Switzerland). Endocrinologists
practicing in proximity to the Delhi slum areas agreed to manage patients
diagnosed with possible diabetes. Patients who did not want to get tested
for diabetes continued to receive TB treatment and care. OpASHA obtained
permission from the National TB program (New Delhi, India) to use an-
onymised data for research and public health purposes without informed
consent.
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Between 2013 and 2015 a total of 1773 patients were screened for dia-
betes by trainedOpASHApersonnel and identified 336 patients with plasma
glucose >6.1 mmol/L (table 8.1, figure 8.1). Of these cases with elevated
glucose, 66 displayed levels above 11.1 mmol/L and were therefore con-
sidered as having diabetes without further testing. Age was significantly
higher in the patient group with glucose values above 6.1 but below 11.1
mmol/L with 42 years compared to 27 years in those with glucose val-
ues equal or below 6.1 mmol/L (table 8.1). Age was equally higher in
patients with glucose values above 11.1 mmol/L compared to the other
groups. Overall, more men participated in the screening, notably in the age
groups 30 to 69 years (figure 8.2A). Yet, these gender proportions did not
differ at significant levels when stratified by glucose values (table 8.1, fig-
ure 8.2B). The most common presentation was pulmonary TB (42%, 95% CI
39.7-44.3%). Of all patients, 49.8% (47.5 – 52.1%) were new cases that had
not been treated before. Re-treatment cases represented 3.8% (3 – 4.8%)
while 3.1% (2.4 – 4%) were relapses (figure 8.3 A and B). For 43% (40 –
45%) these data were not available. According to the TANDEM two-step
diagnostic algorithm, in total 336 patients would qualify for point-of-care
HbA1C testing. Among these patients, 66 (4% of total) were found to have
diabetes based on glucose levels alone. Of these 66 patients, 20 were known
diabetics and already on treatment.
Our investigation shows that random glucose sampling is feasible in
Indian urban slums upon appropriate training of staff. We found high
numbers of patients with elevated random glucose levels. However, to
accurately diagnose diabetes in this setting and to follow the TANDEM
diagnostic algorithm, local point-of-care HbA1c testing is indispensable.
Limitations of this study include challenging data collection that resulted
in missing data and incorrect glucose value entry in five cases. The volun-
tary nature of the glucose measurement could be subject to unaccounted
selection bias. It is important to provide diabetes screening to all TB pa-
tients, notably vulnerable TB patients that reside in slum conditions and
are not under treatment through a national TB program. Both national pro-
grams as well as NGOs caring for TB patients should therefore implement
routine diabetes screening using random glucose sampling as a first step














Age groups of participants
Female 
 total n = 763
 elevated n = 139 (18%)
 mean = 5.8 (SD = 2.7)
Male 
 total n = 1005
 elevated n = 197 (19%)
 mean = 5.9 (SD = 2.6)
NA 
 total n = 5
 elevated n = 0 (0%)





















Figure 8.2: Age and glucose values by sex. A) Age distribution by sex
illustrates that more men participated in the screening, notably in the age
groups 20 - 69. B) Glucose screening results for men and women reveals no
difference in elevated glucose values for either gender. Data analysed and
visualised in R version 3.4.3 and the add-on package tidyverse.
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 elevated n = 68 (15%)
 mean = 5.5 (SD = 1.9)
NA 
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Glucose levels per TB location
NA 
 total n = 765
 elevated n = 134 (17%)
 mean = 5.7 (SD = 2.4)
New 
 total n = 884
 elevated n = 168 (19%)
 mean = 5.9 (SD = 2.6)
Relapse 
 total n = 55
 elevated n = 15 (27%)
 mean = 6.2 (SD = 3.3)
Rx after default 
 total n = 69
 elevated n = 19 (27%)






















Figure 8.3: Glucose values by treatment group and disease location. A)
Glucose levels per treatment group categorised into new cases, relapse
cases and re-treatment cases after default. B) Glucose levels per disease
location divided into pulmonary and extra-pulmonary TB. NA = not avail-
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